

Giovanni Luca Ceresoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1724473/publications.pdf>

Version: 2024-02-01

97
papers

5,643
citations

136950

32
h-index

76900

74
g-index

99
all docs

99
docs citations

99
times ranked

5924
citing authors

#	ARTICLE	IF	CITATIONS
1	Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5786.	4.1	9
2	Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. <i>Clinical Lung Cancer</i> , 2021, 22, 361-370.e3.	2.6	8
3	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1583-1592.	4.2	12
4	Immune checkpoint inhibitors in mesothelioma: a turning point. <i>Lancet, The</i> , 2021, 397, 348-349.	13.7	15
5	Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE. <i>Journal of Bone Oncology</i> , 2021, 26, 100341.	2.4	4
6	P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 653497.	2.8	8
7	A reply to "managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy" <i>Lung Cancer</i> , 2021, 157, 165-166.	2.0	2
8	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2021, 22, 1438-1447.	10.7	45
9	RAMES study: is there really a role for VEGF inhibition in mesothelioma? " Authors' reply. <i>Lancet Oncology, The</i> , 2021, 22, e533.	10.7	1
10	Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. <i>Lung Cancer</i> , 2020, 140, 71-79.	2.0	8
11	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. <i>Lung Cancer</i> , 2020, 140, 59-64.	2.0	33
12	1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). <i>Annals of Oncology</i> , 2020, 31, S1078.	1.2	2
13	Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?. <i>Lung Cancer</i> , 2020, 145, 208-210.	2.0	12
14	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1580-1590.	1.6	189
15	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019, 123, 98-105.	2.5	70
16	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. <i>Lung Cancer</i> , 2019, 134, 210-217.	2.0	12
17	Approved and emerging treatments of malignant pleural mesothelioma in elderly patients. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1179-1188.	2.5	1
18	Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3775-3782.	2.4	10

#	ARTICLE	IF	CITATIONS
19	In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma. Nuclear Medicine Communications, 2019, 40, 1179-1186.	1.1	4
20	Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2019, 20, 82-87.	2.6	19
21	Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma. , 2019, , 221-233.		0
22	Abstract CT202: Safety of Tumor Treating Fields delivery to the torso: Pooled analysis from TTFIELDS clinical trials. , 2019, , .		1
23	Abstract CT201: Final results of Phase II STELLAR trial: TTFIELDS with chemotherapy in unresectable malignant pleural mesothelioma. Cancer Research, 2019, 79, CT201-CT201.	0.9	5
24	Multicentre, double-blind, randomised phase II study evaluating gemcitabine with or without ramucirumab as II line treatment for MPM. Annals of Oncology, 2018, 29, viii644.	1.2	0
25	Italian Nivolumab Expanded Access Program in Non-Squamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. Journal of Thoracic Oncology, 2018, 13, 1146-1155.	1.1	77
26	Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2018, 36, 8568-8568.	1.6	0
27	Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.. Journal of Clinical Oncology, 2018, 36, 8566-8566.	1.6	0
28	Immune checkpoint inhibitors in malignant pleural mesothelioma. Lancet Oncology, The, 2017, 18, 559-561.	10.7	18
29	Prognostic and predictive role of [¹⁸ F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. Cancer Medicine, 2017, 6, 2287-2296.	2.8	22
30	Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. Cytokine and Growth Factor Reviews, 2017, 36, 25-31.	7.2	8
31	Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. Cancer Management and Research, 2017, Volume 9, 789-800.	1.9	16
32	Clinical staging of malignant pleural mesothelioma: current perspectives. Lung Cancer: Targets and Therapy, 2017, Volume 8, 127-139.	2.7	16
33	Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014). BMC Cancer, 2017, 17, 493.	2.6	6
34	Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM). Annals of Oncology, 2017, 28, vi59.	1.2	0
35	Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2017, 35, 8506-8506.	1.6	1
36	Trabectedin (T) as second line treatment option for patients with epithelioid malignant pleural mesothelioma (MPM) in progression following pemetrexed/platin-derivates chemotherapy: ATREUS trial.. Journal of Clinical Oncology, 2017, 35, 8513-8513.	1.6	2

#	ARTICLE	IF	CITATIONS
37	ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.. Journal of Clinical Oncology, 2017, 35, TPS8582-TPS8582.	1.6	7
38	Intermittent maintenance treatment with bevacizumab in patients with metastatic colorectal cancer: A single centre experience.. Journal of Clinical Oncology, 2017, 35, 776-776.	1.6	1
39	Clinical outcome of EGFR-mutant NSCLC patients continuing TKIs beyond progression in combination with local ablative radiotherapy.. Journal of Clinical Oncology, 2017, 35, e20662-e20662.	1.6	0
40	Prognostic value of neutrophil-to-lymphocyte ratio in advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with a tyrosine-kinase inhibitors: A retrospective analysis in a series of western patients.. Journal of Clinical Oncology, 2017, 35, e23045-e23045.	1.6	0
41	Predictive impact of different exon 19 deletions in EGFR-mutant NSCLC treated with first-line TKIs.. Journal of Clinical Oncology, 2017, 35, e20608-e20608.	1.6	0
42	Radiotherapy to intervention sites in mesothelioma: no more?. Lancet Oncology, The, 2016, 17, 1025-1027.	10.7	3
43	Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges. Expert Review of Anticancer Therapy, 2016, 16, 673-675.	2.4	9
44	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology, 2016, 27, 417-423.	1.2	122
45	Vinflunine (VFL) in patients (pts) with metastatic transitional cell carcinoma of the urothelial tract (mTCCU): Clinical outcome and prognostic factors in a nationwide, real-life setting (MOVIE trial).. Journal of Clinical Oncology, 2016, 34, e16031-e16031.	1.6	2
46	Final results of a phase II study of oral vinorelbine (NVBo) monotherapy in patients (pts) with advanced EGFR-positive non-small-cell lung cancer (NSCLC) after failure of EGFR-TKI in first line (NAVOTRIAL 2).. Journal of Clinical Oncology, 2016, 34, e20546-e20546.	1.6	0
47	Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 667-675.	6.4	42
48	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Annals of Oncology, 2015, 26, 2107-2113.	1.2	85
49	Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma. Cancer Treatment Reviews, 2015, 41, 853-858.	7.7	11
50	CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?. Cancer Immunology, Immunotherapy, 2015, 64, 105-112.	4.2	18
51	MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data. Oncotarget, 2015, 6, 42053-42066.	1.8	20
52	Clinicopathological features of patients with malignant mesothelioma in a multicenter, retrospective study.. Journal of Clinical Oncology, 2015, 33, e12651-e12651.	1.6	0
53	Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice. Lung Cancer Management, 2014, 3, 263-271.	1.5	3
54	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. Journal of Clinical Oncology, 2014, 32, 471-471.	1.6	8

#	ARTICLE	IF	CITATIONS
55	Anti-angiogenic therapies for malignant pleural mesothelioma. Expert Opinion on Investigational Drugs, 2012, 21, 833-844.	4.1	13
56	Adjuvant radiotherapy for malignant pleural mesothelioma: Challenges and pitfalls. Radiotherapy and Oncology, 2012, 105, 271.	0.6	0
57	FDG PET/CT metabolic tumour volume in small-cell lung cancer: better staging and prognostic stratification for an improved therapeutic strategy. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 921-924.	6.4	7
58	Malignant pleural mesothelioma (MPM) in elderly patients: A multicenter survey.. Journal of Clinical Oncology, 2012, 30, 7082-7082.	1.6	0
59	Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin. Clinical Cancer Research, 2011, 17, 2581-2590.	7.0	94
60	In Response to Dr. Russi and Colleagues. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1279-1280.	0.8	0
61	Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma. Journal of Clinical Oncology, 2011, 29, e529-e531.	1.6	9
62	Prostatic Stromal Tumor with Fatal Outcome in a Young Man: Histopathological and Immunohistochemical Case Presentation. Rare Tumors, 2010, 2, rt.2010.e57.	0.6	21
63	Imaging in pleural mesothelioma: A review of Imaging Research Presented at the 9th International Meeting of the International Mesothelioma Interest Group. Lung Cancer, 2010, 70, 1-6.	2.0	41
64	Second-line treatment for malignant pleural mesothelioma. Cancer Treatment Reviews, 2010, 36, 24-32.	7.7	78
65	Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer, 2008, 112, 1555-1561.	4.1	89
66	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. British Journal of Cancer, 2008, 99, 51-56.	6.4	107
67	Primary pulmonary meningioma. Lung Cancer, 2008, 62, 401-407.	2.0	73
68	Molecular Alterations in Spontaneous Sputum of Cancer-Free Heavy Smokers: Results from a Large Screening Program. Clinical Cancer Research, 2008, 14, 1913-1919.	7.0	52
69	Is gemcitabine cost effective in cancer treatment?. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 239-249.	1.4	1
70	Optimizing Anti-EGFR Strategies in Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 267-275.	0.3	0
71	Multidisciplinary Treatment of Malignant Pleural Mesothelioma. Oncologist, 2007, 12, 850-863.	3.7	49
72	Assessment of tumor response in malignant pleural mesothelioma. Cancer Treatment Reviews, 2007, 33, 533-541.	7.7	56

#	ARTICLE	IF	CITATIONS
73	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. Expert Opinion on Medical Diagnostics, 2007, 1, 183-191.	1.6	2
74	Role of Computed Tomography and [18F] Fluorodeoxyglucose Positron Emission Tomography Image Fusion in Conformal Radiotherapy of Non-Small Cell Lung Cancer: A Comparison with Standard Techniques with and without Elective Nodal Irradiation. Tumori, 2007, 93, 88-96.	1.1	18
75	Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer. Investigational New Drugs, 2007, 25, 559-564.	2.6	2
76	Short Schedule of Cisplatin and Vinorelbine: A Dose-Finding Study in Non-Small-Cell Lung Cancer. Oncology, 2006, 71, 229-236.	1.9	1
77	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2006, 17, 1120-1127.	1.2	93
78	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. British Journal of Cancer, 2005, 93, 1334-1340.	6.4	73
79	Target delineation in post-operative radiotherapy of brain gliomas: Interobserver variability and impact of image registration of MR(pre-operative) images on treatment planning CT scans. Radiotherapy and Oncology, 2005, 75, 217-223.	0.6	54
80	Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer Patients. Journal of Clinical Oncology, 2005, 23, 5007-5018.	1.6	367
81	Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2005, 97, 643-655.	6.3	1,517
82	Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Annals of Oncology, 2004, 15, 1042-1047.	1.2	322
83	Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2004, 96, 1133-1141.	6.3	367
84	Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 6006-6012.	7.0	40
85	Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). British Journal of Cancer, 2004, 90, 82-86.	6.4	52
86	Anatomic Variations Due to Radical Prostatectomy. Strahlentherapie Und Onkologie, 2004, 180, 563-572.	2.0	26
87	Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. International Journal of Radiation Oncology Biology Physics, 2004, 59, 674-683.	0.8	42
88	Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. Lung Cancer, 2004, 44, 231-239.	2.0	21
89	Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). International Journal of Radiation Oncology Biology Physics, 2003, 55, 688-694.	0.8	112
90	Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiotherapy and Oncology, 2003, 67, 275-283.	0.6	253

#	ARTICLE	IF	CITATIONS
91	Gefitinib in Pretreated Non-Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC. <i>Journal of Clinical Oncology</i> , 2003, 21, 2658-2663.	1.6	213
92	Mediastinal follicular dendritic cell sarcoma. <i>Haematologica</i> , 2003, 88, ECR04.	3.5	11
93	Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment. <i>Cancer</i> , 2002, 95, 605-612.	4.1	159
94	Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2001, 34, 279-287.	2.0	109
95	Irradiation Fields and Doses in Glioblastoma Multiforme: Are Current Standards Adequate?. <i>Tumori</i> , 2001, 87, 85-90.	1.1	2
96	Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 651-658.	0.8	71
97	Evaluation of radiological and pathological prognostic factors in surgically-treated patients with bronchoalveolar carcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , 2001, 20, 367-371.	1.4	31